Core Insights - The National Medical Products Administration (NMPA) has announced measures to optimize the lifecycle regulation of high-end medical devices, focusing on areas such as medical robots, high-end medical imaging equipment, AI medical devices, and new biological materials [1] - The global high-end medical device market is projected to exceed $1.8 trillion by 2030, with China's market expected to reach 2.8 trillion RMB [1] Industry Focus Areas - **Brain-Computer Interface (BCI)**: The BCI market in China is expected to reach 3.2 billion RMB in 2024, growing at 18.8%, and is projected to reach 5.58 billion RMB by 2027 with a growth rate of 20%. Challenges include technical bottlenecks and ethical controversies [2] - **High-End Medical Imaging Equipment**: The domestic market has seen rapid development, with increasing localization in mid-to-low-end products. However, high-end imaging equipment still faces challenges, particularly in the localization of key components [2] - **Surgical Robots**: The market for surgical robots is dominated by laparoscopic surgical robots, with the Da Vinci system currently leading. Domestic products are entering the market, which may disrupt the current landscape [3] - **High-Value Consumables**: These account for about 20% of the medical device market. While some segments have achieved domestic substitution, others, particularly in cardiac and neurological devices, still rely heavily on imports [3] - **In Vitro Diagnostics (IVD)**: The IVD industry has seen significant domestic advancement in low-end technologies, but high-end segments remain largely dominated by foreign brands [3] Market Trends - The medical device industry is characterized by a dual focus on technology-driven innovation and domestic substitution. Key components for high-end devices are being developed domestically, with some products nearing international standards [4] Related Companies - **MicroPort Scientific Corporation (微创机器人)**: Reported over 130 core product orders, with significant growth in laparoscopic surgical robots [5] - **Yimai Sunshine (一脉阳光)**: Engaged in building medical imaging centers and has launched an AI medical imaging model, marking a transition in the industry [6] - **Yongsheng Medical (永胜医疗)**: Focuses on rehabilitation robotics and has secured agreements for health care product procurement [6] - **Kangji Medical (康基医疗)**: Recently received regulatory approval for a four-arm laparoscopic surgical robot, expanding its clinical application range [7]

双机配置，为区域输送人才。作为国内顶尖医疗科技企业——"微创"公司精心布局的全国核心培训基地 之一，东营市人民医院配置双机，一台直接投入临床一线，服务患者；另一台则专用于区域人才孵化， 构建起"理论+高仿真实操"的先进培训体系，为山东地区外科医师提供沉浸式操作平台。 东营市人民医院5G胸腹腔内窥镜手术系统（手术机器人）启用暨区域培训基地的授牌，是推动医院高 质量发展、满足群众高品质医疗需求的关键一步，标志着医院微创外科技术迈入了智能化、精准化的新 时代。它将在泌尿、普外、妇科、胸外科等高难度手术中发挥巨大作用，为患者带来更优质的诊疗体 验。医院将以此次胸腹腔手术机器人启用为契机，强化技术培训、规范临床应用，积极推动多学科协作 与创新，让这项技术惠及更多患者。 启用仪式上，上海微创医疗机器人（集团）股份有限公司执行董事及首席商务官刘雨为东营市人民医院 5G胸腹腔内窥镜手术系统区域培训基地授牌。上海市第一人民医院副主任医师、硕士研究生导师、泌 尿肿瘤外科治疗组组长蒋琪、上海微创医疗机器人（集团）股份有限公司执行董事及首席商务官刘雨分 别授课，介绍5G胸腹腔内窥镜手术系统（手术机器人）和5G远程技术的应用。东营市人 ...

Group 1: Market Overview - The ongoing conflict between Iran and Israel is causing market volatility, with the Hang Seng Index recently closing with a bearish candlestick pattern [2] - The market is closely monitoring the potential for escalation in the Iran-Israel conflict, with expectations that large-scale conflict is unlikely due to diplomatic efforts from the US and Russia [2][6] - The upcoming Federal Reserve interest rate decision on June 19 is anticipated to be influenced by rising oil prices, which have dampened expectations for a rate cut [2] Group 2: Oil and Shipping Industry - The intensity of the Iran-Israel conflict could significantly impact oil shipping rates, particularly if Iranian oil exports are disrupted, potentially removing 1.8 million barrels per day from the market [6] - The shipping sector is expected to be influenced by the geopolitical situation, with a focus on how the conflict may affect oil and gas negotiations and the potential for US intervention [6][7] - The sentiment surrounding the Iran-Israel conflict is expected to catalyze movements in shipping stocks, particularly those involved in oil transportation [8] Group 3: Investment Opportunities - The company MicroPort Scientific Corporation (02252) is projected to benefit significantly from the growing laparoscopic surgical robot market, with a forecasted compound annual growth rate of 43% from 2025 to 2030 [4] - The laparoscopic surgical robot market in China is expected to reach 11.2 billion RMB by 2030, with a compound annual growth rate of 21% over the next five years [5] - The company is positioned to capitalize on its cost advantages and comparable functionality to leading systems, which may enhance its market share in both domestic and international markets [5]

智通财经APP讯，微创机器人-B(02252)发布公告，根据公司内部初步统计数据，截至本公告日期，集团 旗下腔镜、骨科、血管介入核心产品的综合订单量累计超130台。其中，图迈腔镜手术机器人(图迈)于 全球范围内累计商业化订单超70台(2025年全球新签商业化订单近20台)，累计商业化装机突破50台。同 时，图迈不断加速推进大规模、常态化临床应用的开展，截至目前，图迈全球范围内人体临床手术量累 计已突破万例。 继2025年4月图迈远程手术全科室应用获得全球首个注册批准后，公司持续在远程手术临床应用领域不 断探索。图迈近期辅助比利时的外科专家连续完成两例远程手术，也是欧洲首次机器人辅助远程人体手 术。本次手术采用医院常规网络(V-LAN)传输通路，双向延时仅20毫秒，充分保证了远程机器人手术所 需操作精确达毫秒级水平的技术要求，进一步证明图迈采用的图像低时延超压缩技术、数据多维加密技 术、动态通讯网络优化策略、复杂网络环境下手术安全保障机制等远程手术技术体系的先进性。 产品注册方面，2025年截至本公告日，图迈于超过10个国家或地区获得注册认证，全球累计获证国家或 地区超过30个。图迈的临床有效性、稳定性和安全性 ...

Core Viewpoint - The surgical robotics industry in China is experiencing rapid growth and transformation, driven by advancements in technology such as smart algorithms and 5G, leading to increased market penetration and commercialization of surgical robots [1][3]. Industry Overview - The penetration rate of surgical robots in China has risen from 3.7% in 2020 to an expected 11.2% by 2025, with minimally invasive surgeries accounting for 68% of applications [1]. - The market size for surgical robots in China reached 71.7 billion yuan in 2023 and is projected to exceed 100 billion yuan by 2025, potentially surpassing 287 billion yuan by 2030 [3]. Technological Advancements - Surgical robots are becoming essential tools in clinical settings, enhancing precision and reducing recovery times for patients [2]. - The integration of 5G technology is enabling remote surgical operations, allowing surgeons to perform procedures from great distances, thus addressing regional disparities in healthcare access [8][10]. Domestic Development - The domestic production rate of surgical robots has exceeded 80%, with a significant increase in the number of approved products, indicating a shift from reliance on foreign technology to local innovation [1][4]. - By the end of 2024, 64 companies are expected to have a total of 115 surgical robot products approved, with domestic brands accounting for 81.7% of these approvals [4]. Market Dynamics - The Chinese market is characterized by a diverse ecosystem with multiple technological pathways and applications, unlike the more consolidated markets in Europe and the U.S. [7]. - Companies like MicroPort and Tianzhihang are making significant strides in both domestic and international markets, with products that have received approvals in multiple regions [7]. Future Outlook - The surgical robotics industry is anticipated to enter a phase of accelerated growth, particularly with the advent of remote surgical capabilities powered by 5G technology [9][10]. - The global market for remote surgical robots is expected to see explosive growth, with China emerging as the second-largest market after North America [9].

在康复治疗场景中，机器人先演示一遍康复训练动作，接着偏瘫患者跟着做一遍，机器人通过视觉和触 觉进行效果反馈；在医院前台，机器人通过视觉感知和大模型交互为老年患者提供导诊服务...... 这是目前傅利叶与上海国际医学中心的康复中心合作打造的"人形+康复"概念应用场景。成立于2015年 的傅利叶最早从医疗康复机器人切入市场，并于2017年推出了国内首款商业化的下肢外骨骼机器人，逐 步形成覆盖上肢、下肢、平衡训练等全产品矩阵。据悉，在深耕多年的康复场景，傅利叶已陆续推出超 30款智能康复产品，并为全球60余个国家和地区、3000余家医疗机构提供专业服务。 人形机器人在医疗康养领域能做哪些事情？目前，具身智能在医疗场景落地还面临着哪些难题？近期， 南方都市报"走进未来产业"课题组来到位于上海张江机器人谷的上海傅利叶智能科技有限公司（以下简 称"傅利叶"）进行调研，并实地走访了"傅利叶智能康复港"。 打造国内首个"人形+康复"的概念应用场景 为全面推动人形机器人在康复领域的实践探索，近期，傅利叶与上海国际医学中心举行了"具身智能康 复港"揭牌仪式，双方将围绕具身智能机器人在康复医疗场景的应用标准建设、康复方案共创、科研 ...

一则"折让配售"公告近日可谓让微创机器人-B(02252)"有苦难言"。 5月14日，微创机器人发布公告宣布配售2513.65万股新H股，每股作价15.5港元，较上一交易日(5月13日)收盘价17.98港元折让约13.79%，净筹约 3.82亿港元。这是公司自2024年6月、12月以来的第三次折价配股。 同日，其控股股东上海默化人工智能科技宣布以相同价格出售3016万股，金额约4.68亿港元。紧随配售事项及出售事项完成后，微创机器人控股股 东持股比例将从48.08%降至43.98%，公司总股本稀释约2.44%。 受上述消息影响，微创机器人连跌两日——5月14日、15日，其股价分别下跌8.12%、4.84%，截止目前股价报于15.72港元，总市值为158.17亿元。 不得不说，市场用脚投票显然也暴露了当前投资者对微创机器人信心不足的现象，而隐藏在这一现象之下的则是公司避不可避的"现金流之困"。 营收高增，盈利难仍待解 由于行业高投入、长周期的特性，微创机器人目前仍深陷"营收高增长，仍未找到盈利之道"的怪圈。 据年报数据披露，2024年，该公司营业总收入2.57亿元，同比增长145.95%。增长主要得益于国内外市 ...

关注我们，带你洞见医疗的未来！MedTrend医趋势——专注于医疗医药、生命科学、医院领域，为您提供及时、实用的热点资讯、市场概况、行业趋势 等精彩内容，旨在建设全面、周到、专业的信息分享与交流平台。 以下文章来源于MedTrend医趋势 ，作者更多精彩 MedTrend医趋势 . 2025年初到现在，全国腔镜手术机器人中标量同比暴涨150%，达成3.38亿采购订单。 据中国政府采购网显示：截至5月7日，进口巨头达芬奇以12台订单稳坐头把交椅，但精锋、微创等国产品牌以价格利刃撕开8台缺口，在中高端市场 形成实质性威胁。 与此同时，上半年就有微创医疗、瑞龙外科、敏捷医疗、唯精医疗、术锐国产腔镜手术机器人获批NMPA上市，5家"围攻"达芬奇。 此外，关税"核弹"已引爆，中美125%关税互击政策正式落地，进口达芬奇系统终端价将飙升，成本压力倒逼医院转向国产替代。 作者 | 龚瑞 来源 | MedTrend医趋势 导 语：仅上半年就有微创医疗、瑞龙外科、敏捷医疗、唯精医疗、术锐国产腔镜手术机器人获批NMPA上市，5家"围攻"达芬奇。 在资本市场，手术机器人是最热门的赛道之一，备受青睐。2025年随着国产替代加速，二级 ...

【解剖大盘】 四月最后一天，港股走势还不错，恒指涨了0.51%，虽然没看到大举的突破，但给5月行情带来了预 期。 当下的环境依旧朝着相对有利的方向在走。近两个月，美国不少进口商已经提前大批量囤货，以缓和关 税的冲击。受此影响，美国3月份商品贸易逆差扩大至创纪录的1620亿美元，大大超过了经济学家预估 的1450亿美元，也超过了前值1479亿美元。在消费品进口的带动下，美国3月份进口增长5%至3427亿美 元。当月出口增长1.2%。不过，接下来才是考验，零售商还有大约五到七周的库存，然后消费者们的 购物选择将会明显减少。 摩根大通资产管理公司美洲首席市场策略师加布里埃拉·桑托斯(GabrielaSantos)表示，对特朗普来 说，"用来下调对华关税的剩余时间不多了。" 当地时间周二，美国商务部长霍华德·卢特尼克透露，特朗普政府已达成首份贸易协议，但尚未完全敲 定。 此前一天，贝森特声称，美国已经在谈判中取得了进展，他预计第一份贸易协议可能会在本周或下周达 成。他声称，美国和印度有可能在未来几天内达成协议，这是美国与15至18个"重要贸易关系"伙伴达成 的定制协议之一。 美国现在不断在吹嘘所谓的成果，主要还是为了 ...

【主编观市】 在特朗普关税战"认怂"之下，港股上周也同步反弹。不过，市场观望情绪依旧浓厚，因为变数太多。单 边的嘴炮并没有解决根本性问题。 上周的重磅会议也提前召开，但预期不算强，继续以稳为主，以不变应万变。短期强刺激难以看到。 本周持续关注美国方面动态，美股"七巨头"中的苹果、微软、亚马逊和Meta本周都将披露财报，关注 业绩及供应链情况。美欧一季度GDP将公布、美国4月非农就业报告，重点看数据出台是否引发衰退的 担忧。 本周六晚间伯克希尔·哈撒韦将公布一季度财报并举行年度股东会。由于巴菲特年事已高，今年的问答 环节会缩短一些，将在奥马哈当地时间早上8点至下午1点间举行。投资重点观察其现金变动情况及对后 市展望。 接下来是五一假期，市场最后一天或对五月行情进行定调。 当前看，科技和刺激内需或成为主要方向。科技线：高层举行集体学习，主题聚焦人工智能(AI)。 Manus母公司海外融资超5亿美元，聚焦中东、日本等海外市场开拓。天津市正研究推出"算力券"政 策，用于支持企业购买智算或超算服务。预计AI智能体、算力等会有刺激。 消费线：预计系列刺激内需的政策红包陆续会发布。商务部等6部门：下调离境退税起退点，优化离 ...